Mitomycin C
Mutamycin · Antitumor antibiotic
Prototype dose-dependent TMA.
Gemzar · Gem
Nucleoside analog · approved 1996 · 14 citations · FAERS AKI reporting ROR 2.36 (95% CI 2.24–2.50, 1,326 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The silent TMA — new hypertension months in is the warning sign.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
0.008–0.078% range across studies
Estimates span three orders of magnitude by ascertainment. The only figure with a real denominator is the manufacturer safety-database review: 12 cases against 78,800 patient exposures, a crude 0.015% (range 0.008–0.078%). The product characteristics give 0.01%. Against that, a single center reported 2.7% — four of its five cases on nab-paclitaxel/gemcitabine, where a pharmacokinetic interaction is suspected. Historically high mortality: of 23 cases with reported outcome in the literature tally, 11 died within a few weeks, death directly attributed to HUS in two.Source: Fung et al., Cancer 1999 (PMID 10223245); Allard et al., Eur J Clin Pharmacol 2022 (PMID 35507073); Walter et al., Am J Kidney Dis 2002 (PMID 12324937)
TMA emerges after months of cumulative exposure, not from a single dose.
Distilled from: “Delayed — months of cumulative exposure.”
Once TMA is suspected the drug is stopped permanently; rechallenge risks recurrence and worse renal outcomes.
Renal recovery is genuinely split. Renal-limited TMA can reverse after prompt, permanent drug cessation, but a meaningful subset progresses to dialysis-dependent kidney failure or chronic CKD despite discontinuation. Discontinuation is the key intervention — dose reduction neither prevents nor reverses it, and plasma exchange is generally ineffective (this is not classic TTP).PMID 12324937 (opens PubMed in a new tab)
Median cumulative dose ~20 g/m2 (range ~2.5-48 g/m2), reached over roughly 22 doses and a mean of ~7.4 months of therapy (median onset ~8 months).
A cumulative-dose/duration phenomenon rather than an idiosyncratic single-dose reaction: risk rises with prolonged exposure, so vigilance must persist throughout treatment. Dose reduction does not prevent it — once TMA is suspected the drug must be permanently discontinued.PMID 12324937 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Cumulative incidence 0.31% (8 of 2,586 patients) in the largest single-institution series, higher than the earlier 0.015% estimate; new or worsening hypertension preceded the diagnosis in 7 of 9 cases.
Not the same figure as §01's 0.015%. §01 is the manufacturer's crude estimate across 78,800 exposures; this row is one health system's chart review (8 of 2,586 treated patients), which found a higher incidence than previously reported (0.31% vs 0.015%).
New or exacerbated hypertension is a prominent early feature of gemcitabine-associated TMA, seen in 7 of 9 patients and often preceding TMA diagnosis by 0.5-10 weeks. PMID 15197810 (opens PubMed in a new tab)
Glomerular endothelial injury underlies the TMA lesion; gemcitabine is listed among conventional chemotherapies causing glomerular disease, but standalone incidence is case-level with no citable rate. PMID 35190107 (opens PubMed in a new tab)
Intravesical instillation only - chemical/follicular cystitis in NMIBC trials, not a systemic-route toxicity.
Tap a signature to trace where it strikes the nephron.
Representative incidence · 0.008–0.078% range across studies
Thrombotic Microangiopathy strikes: Glomerulus, Vasculature / Endothelium.
Thrombotic Microangiopathy
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Nucleoside analog incorporated into DNA, causing chain termination and inhibiting ribonucleotide reductase. Pancreatic, bladder, lung, breast and ovarian cancer.
Class-level context for the major non-renal toxicities of the Nucleoside analog class.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Hematologic
Cytopenias, thrombosis, TMA
Pulmonary
Pneumonitis, ILD, effusions, hypertension
10 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Everything below is FAERS — adverse events someone chose to report, about 54,066 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
10,142 of 54,066 reports
Reported with hospitalization
21,419 of 54,066 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 8,842 of the 54,066 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Gemcitabine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Mutamycin · Antitumor antibiotic
Prototype dose-dependent TMA.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
VEGFR TKI
Hypertension as an on-target marker; proteinuria.
Votrient · VEGFR TKI
VEGFR-TKI; hypertension, proteinuria, TMA.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Gemcitabine’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Gemcitabine; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 220 clinical records among the 300 most-relevant of 327 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.